ArticleProbiotics and antimicrobial proteins2025
Akkermansia muciniphila Akk11 Supplementation Attenuates MPTP-Induced Neurodegeneration by Inhibiting Microglial NLRP3 Inflammasome.
Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Akkermansia muciniphila : A next-generation gut probiotic supporting neurorepair and functional recovery.Neural regeneration research · 2026Article
- A Dual-Target Microbial Therapeutic Strategy for Treating Metabolic Diseases: Complementary Mechanisms and Clinical Prospects ofMetabolites · 2026Review
- Insights into the Functions, Characteristics, and Mechanisms of Disease-Related Proteins fromMicroorganisms · 2026Review
- Roseburia intestinalis Offers Vagus-Dependent Neuroprotection Against Parkinson's Disease.Molecular neurobiology · 2026Article
- NLRP3 Inflammasome Activation in Oxidative Stress: A Key Mechanism Driving Neuroinflammation.Neuroimmunomodulation · 2026Review
- GDNF signaling modulation by Akkermansia muciniphila ameliorates constipation-depression comorbidity in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Strain-Specific Safety Evaluation ofFood science & nutrition · 2025Article
- Gut Microbiome as a Source of Probiotic Drugs for Parkinson's Disease.International journal of molecular sciences · 2025Review
- An Updated and Comprehensive Review Exploring the Gut-Brain Axis in Neurodegenerative Disorders and Neurotraumas: Implications for Therapeutic Strategies.Brain sciences · 2025Review
- Investigating the role ofFrontiers in microbiology · 2025Article
- An analysis of electroacupuncture as adjunctive treatment for insomnia: a new perspective targeting GABA-mediated microbiome-gut-brain axis.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut dysbiosis is associated with the progression of Parkinson's disease (PD). Probiotics have been demonstrated to impact disease progression via the gut-brain axis. This study aims to investigate the therapeutic potential of Akkermansia Muciniphila Akk11 (Akk11) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model. Our results indicated that Akk11 administration significantly improved the MPTP-induced behavioral abnormalities, reduced the loss of dopaminergic neurons, microglia activation, reversed the production of inflammatory cytokines, and colonic damage. Mechanistic studies showed that Akk11 administration suppressed inflammatory responses by inhibiting microglial NLRP3 inflammasome activation. In summary, Akk11 alleviated MPTP-induced motor deficits and neural damage by inhibiting microglial NLRP3 inflammasome. These findings suggest that Akk11 supplementation has therapeutic potential in treating PD through the gut-brain axis.
Indexed as
Identifiers
40048129What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.